These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 127379

  • 1. Soluble fibrin complex production and proteolysis during ancrod therapy.
    McKillop C, Edgar W, Prentice CR, Forbes CD.
    Scott Med J; 1975 May; 20(3):139-40. PubMed ID: 127379
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In vivo production of soluble complexes containing fibrinogen-fibrin related antigen during ancrod therapy.
    McKillop C, Edgar W, Forbes CD, Prentice CR.
    Thromb Res; 1975 Sep; 7(3):361-72. PubMed ID: 1188838
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Ancrod: clinical indications and methods of use.
    Wright JG, Geroulakos G.
    Semin Vasc Surg; 1996 Dec; 9(4):315-28. PubMed ID: 8958608
    [No Abstract] [Full Text] [Related]

  • 8. Ancrod revisited: viscoelastic analyses of the effects of Calloselasma rhodostoma venom on plasma coagulation and fibrinolysis.
    Nielsen VG.
    J Thromb Thrombolysis; 2016 Aug; 42(2):288-93. PubMed ID: 26905070
    [Abstract] [Full Text] [Related]

  • 9. Fibrinolysis in glomerulonephritis treated with ancrod: renal functional, immunologic and histopathologic effects.
    Kim S, Wadhwa NK, Kant KS, Pollak VE, Glas-Greenwalt P, Weiss MA, Hong CG.
    Q J Med; 1988 Nov; 69(259):879-905. PubMed ID: 3078212
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Relations between the concentration of fibrinogen, thromboplastin time, thrombin time and reptilase time in patients treated with Arwin].
    Paar D, Klüken N.
    Med Welt; 1975 Sep 19; 26(38):1700-1. PubMed ID: 1186461
    [No Abstract] [Full Text] [Related]

  • 12. Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis.
    Glas-Greenwalt P, Kant KS, Dosekun A, Frazier J, Allen C, Pollak VE.
    J Lab Clin Med; 1985 Jan 19; 105(1):99-107. PubMed ID: 3871465
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Coagulation studies during therapeutic application of arvin.
    Vinazzer H.
    Thromb Res; 1976 Feb 19; 8(2):243-8. PubMed ID: 943132
    [No Abstract] [Full Text] [Related]

  • 16. Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits.
    Krishnamurti C, Young GD, Barr CF, Colleton CA, Alving BM.
    J Lab Clin Med; 1991 Dec 19; 118(6):523-30. PubMed ID: 1744501
    [Abstract] [Full Text] [Related]

  • 17. [Aspects of defibrinogenation therapy].
    Klüken N.
    Phlebologie; 1975 Dec 19; 28(1):39-41. PubMed ID: 1202532
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Early postischaemic renal fibrin deposition and reduction of glomerular filtration rate in the rat: effect of the defibrinating agent Arwin.
    Losonczy G.
    Acta Physiol Hung; 1985 Dec 19; 66(2):183-7. PubMed ID: 4050462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.